Prevalence and risk factors for metabolic syndrome in schizophrenia, schizoaffective, and bipolar disorder.
Saved in:
| Title: | Prevalence and risk factors for metabolic syndrome in schizophrenia, schizoaffective, and bipolar disorder. |
|---|---|
| Authors: | Mohd Ahmed, Hind, Abdel Aziz, Karim, Al Ammari, Abeer, Galadari, Mohammed, Alsaadi, Aaisha, Alhassani, Aysha, Al Marzooqi, Fatima, AlAhbabi, Mohammed, Alsheryani, Hind, Bahayan, Meera, Ahmed, Reem, Alameri, Sara, Stip, Emmanuel, Aly El-Gabry, Dina |
| Source: | International Journal of Psychiatry in Clinical Practice. Mar2024, Vol. 28 Issue 1, p35-44. 10p. |
| Subjects: | Metabolic syndrome risk factors, Bipolar disorder, Cross-sectional method, Vital signs, Body mass index, Schizoaffective disorders, Schizophrenia, Descriptive statistics, Blood sugar, Metabolic syndrome, Comparative studies, Triglycerides, Medical screening, Fasting |
| Geographic Terms: | United Arab Emirates |
| Abstract: | Metabolic Syndrome (MetS) is a risk for developing cardiovascular diseases and its prevalence is especially high in psychiatric patients. To date, there is limited data from the United Arab Emirates (UAE) on the prevalence of MetS. Therefore, we aimed to investigate its prevalence and possible risk factors in a large sample of psychiatric patients in the UAE. A cross-sectional study was conducted at Al-Ain Hospital, in Al-Ain City, UAE. We collected demographic and clinical data on patients diagnosed with schizophrenia, schizoaffective, and bipolar affective disorder in the period between January 2017 and December 2020. This included their secondary diagnosis (psychiatric or medical), vital signs (heart rate, systolic and diastolic blood pressure, Body Mass Index [BMI]), metabolic parameters (fasting blood glucose, cholesterol, triglycerides, low-density lipoprotein, high-density lipoproteins), and prescribed medications. We used the American Association of Clinical Endocrinology (AACE) criteria to diagnose MetS. We included 889 subjects and of these, 79.8% (N = 709) had a BMI ≥25 kg/m2 and 9.8% (N = 87) had no abnormal metabolic parameters. Overall, 28.1% (N = 250) had MetS with no statistical difference between the three groups. Fasting blood glucose levels and abnormally elevated triglycerides were significant predictors for MetS. Our study found that around one in three patients had MetS irrespective of the three diagnoses. Some variables were significant predictors for MetS. Our findings were consistent with other studies and warrant the need for regular screening and management of abnormal metabolic parameters. There is no statistical difference between schizophrenia, schizoaffective disorder, and bipolar disorder with regards to the prevalence of metabolic syndrome. Fasting blood glucose levels and abnormally elevated triglycerides were significant predictors of metabolic syndrome. Screening of metabolic parameters is important as well as the careful tailoring of the choice of antipsychotics. [ABSTRACT FROM AUTHOR] |
| Copyright of International Journal of Psychiatry in Clinical Practice is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Metabolic Syndrome (MetS) is a risk for developing cardiovascular diseases and its prevalence is especially high in psychiatric patients. To date, there is limited data from the United Arab Emirates (UAE) on the prevalence of MetS. Therefore, we aimed to investigate its prevalence and possible risk factors in a large sample of psychiatric patients in the UAE. A cross-sectional study was conducted at Al-Ain Hospital, in Al-Ain City, UAE. We collected demographic and clinical data on patients diagnosed with schizophrenia, schizoaffective, and bipolar affective disorder in the period between January 2017 and December 2020. This included their secondary diagnosis (psychiatric or medical), vital signs (heart rate, systolic and diastolic blood pressure, Body Mass Index [BMI]), metabolic parameters (fasting blood glucose, cholesterol, triglycerides, low-density lipoprotein, high-density lipoproteins), and prescribed medications. We used the American Association of Clinical Endocrinology (AACE) criteria to diagnose MetS. We included 889 subjects and of these, 79.8% (N = 709) had a BMI ≥25 kg/m2 and 9.8% (N = 87) had no abnormal metabolic parameters. Overall, 28.1% (N = 250) had MetS with no statistical difference between the three groups. Fasting blood glucose levels and abnormally elevated triglycerides were significant predictors for MetS. Our study found that around one in three patients had MetS irrespective of the three diagnoses. Some variables were significant predictors for MetS. Our findings were consistent with other studies and warrant the need for regular screening and management of abnormal metabolic parameters. There is no statistical difference between schizophrenia, schizoaffective disorder, and bipolar disorder with regards to the prevalence of metabolic syndrome. Fasting blood glucose levels and abnormally elevated triglycerides were significant predictors of metabolic syndrome. Screening of metabolic parameters is important as well as the careful tailoring of the choice of antipsychotics. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13651501 |
| DOI: | 10.1080/13651501.2024.2310847 |
